Page last updated: 2024-08-24

rubitecan and Lymphoma, Large B-Cell, Diffuse

rubitecan has been researched along with Lymphoma, Large B-Cell, Diffuse in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aggarwal, BB; Mendoza, J; Pantazis, P; Raju, U; Singh, S1

Other Studies

1 other study(ies) available for rubitecan and Lymphoma, Large B-Cell, Diffuse

ArticleYear
Acquisition of cellular resistance to 9-nitro-camptothecin correlates with suppression of transcription factor NF-kappa B activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells.
    Anti-cancer drugs, 1998, Volume: 9, Issue:8

    Topics: Antineoplastic Agents; Camptothecin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Host Cell Factor C1; Humans; Hydrogen Peroxide; I-kappa B Proteins; Interleukin-1; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Octamer Transcription Factor-1; Receptors, Tumor Necrosis Factor; Tetradecanoylphorbol Acetate; Transcription Factor AP-1; Transcription Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

1998